このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke (GABAPLAST)

2026年11月12日 更新者:University Hospital, Toulouse

Effect of GABAergic Treatments on Cortical Plasticity and Motor Learning Capacity in the Subacute Phase After Stroke: a Single-case Experimental Study

The GABAPLAST study explores how commonly prescribed GABAergic drugs prescribed during post-stroke rehabilitation affect cortical plasticity and motor learning capacity. Using a multiple-baseline single-case design, the study evaluates the effects of Baclofen, Oxazepam, and Gabapentin in subacute stroke patients according to their clinical indication. Cortical plasticity capacity is measured with transcranial magnetic stimulation and Paired Associative Stimulation (TMS/PAS). The study aims to determine whether these drugs interfere with or preserve brain plasticity during recovery.

調査の概要

詳細な説明

Scientific rationale Functional recovery after stroke relies on neuroplasticity, the brain's ability to reorganize neural connections. During the subacute phase, high synaptic plasticity allows efficient motor relearning, but GABAergic inhibition may reduce these mechanisms. Several animal and human studies suggest that increased GABAergic activity limits long-term potentiation of plasticity (LTP-like) and motor learning. Baclofen (GABA-B agonist), Oxazepam (GABA-A agonist), and Gabapentin (GABA modulator) are routinely prescribed to treat spasticity, anxiety, or neuropathic pain after stroke, yet their neurophysiological effects remain unclear. GABAPLAST aims to provide the first controlled experimental evidence of their direct influence on cortical plasticity and implicit motor learning in subacute stroke patients.

Treatment/strategy/procedure and follow up

The study comprises 26 repeated assessment sessions performed five times per week, from Monday to Friday, over approximately six weeks. Each participant will receive one of the following medications according to their clinical indication: oxazepam for anxiety; baclofen for spasticity; gabapentin for neuropathic pain. Each participant will undergo two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication;
  • Phase B: phase with exposure to the study medication, including dose titration and treatment at the clinically appropriate dose.

The duration of Phase A will be randomized to 6, 9 or 12 repeated assessments. Phase B will comprise 20, 17 or 14 assessments, respectively, so that each participant completes a total of 26 assessments.

During Phase A, participants in the oxazepam SCED may receive appropriate non-pharmacological usual-care interventions, such as psychological support, relaxation techniques, sophrology or psychotherapy, according to their clinical needs. If immediate pharmacological treatment becomes necessary, the participant will discontinue the study and receive the appropriate treatment without delay.

Medication doses will be adjusted by the investigator according to usual clinical practice, treatment efficacy and tolerability, within the limits defined in the relevant Summary of Product Characteristics and the dose-titration schedules specified in the protocol. Dose changes, dates and reasons for adjustment will be documented in the electronic case report form.

Each assessment session will include: tablet-based motor learning tasks: the Serial Reaction Time Task and Target Jump Task; TMS/PAS assessment of cortical excitability and plasticity; standardized collection of adverse events.

研究の種類

介入

入学 (推定)

12

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Toulouse、フランス、31 059
        • Raymonde Fournet Purpan Hospital - Toulouse University Hospital
        • コンタクト:
        • 主任研究者:
          • Emmeline Montané, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Adults (≥18 years) with ischemic or hemorrhagic stroke in the subacute phase (2 weeks-6 months)
  • Non-urgent clinical indication for oxazepam, baclofen or gabapentin, with the protocol-defined treatment initiation interval considered medically acceptable by the investigator
  • PGI-S score of at least 2 for the symptom leading to treatment prescription
  • Ability to understand and consent (BDAE score >3)
  • Brain MRI available for neuronavigation
  • No motor impairment in the non-paretic hand
  • Affiliation with a national health insurance system
  • Free, informed and written informed consent signed by the participant and the investigator (at the latest on the day of inclusion and before any review required by the research).

Exclusion Criteria:

  • Current or recent treatment, within the previous 7 days, with a gabaergic drug of interest (oxazepam, gabapentin, baclofen)

  • Current or recent treatment, within the previous 7 days, with any prohibited treatment (benzodiazepine, Z-drug, morphine, pregabalin, sedative antipsychotic or barbiturate).

  • History of neurological disorders other than stroke, for example: neurodegenerative disease, multiple sclerosis, epilepsy, brain tumour, hydrocephalus.

  • History of severe psychiatric conditions, such as schizophrenia or bipolar disorder

  • Need for immediate initiation of the planned medication

    • Oxazepam: severe respiratory failure, untreated sleep apnoea syndrome, severe acute or chronic hepatic impairment, myasthenia gravis, hypersensitivity to oxazepam or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
    • Baclofen: hypersensitivity to baclofen or any excipient, wheat allergy, or coeliac disease
    • Gabapentin: hypersensitivity to gabapentin or any excipient, galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
  • Presence of a psychoactive substance dependence

  • Pregnancy or breast-feeding

  • Skin disorder in the stimulated hand indicating the placement of electromyographic collection or stimulation electrodes

  • Medical contraindications for the performance of MSDs according to the TMS safety questionnaire

  • Presence of a major peripheral neuromuscular disorder (e.g. severe motor neuropathy) making the interpretation of PEM unreliable.

  • Guardianship, curatorship, safeguarding of justice

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Baclofen SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, baclofen intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to baclofen, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments.
実験的:Oxazepam SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, oxazepam intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to oxazepam, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments
実験的:Gabapentin SCED

The patient will undergo two phases. The duration of phase A, baseline without treatment, will be randomized to 6, 9 or 12 repeated measures. The duration of phase B, gabapentin intake, will be randomized to 20, 17 or 14 repeated measures. Each participant will serve as their own control, allowing within-subject comparison of outcomes before and after treatment introduction.

Each participant undergoes repeated assessments of cortical plasticity (TMS/PAS) and motor learning (SRTT and Target Jump Task) across two consecutive phases:

  • Phase A: baseline phase without exposure to the study medication, comprising 6, 9 or 12 repeated assessments according to randomized allocation.
  • Phase B: phase with exposure to gabapentin, including dose titration and treatment at the clinically appropriate dose. Phase B comprises 20, 17 or 14 repeated assessments, respectively, so that each participant completes a total of 26 assessments

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Brain plasticity
時間枠:6 weeks

It will be assessed by the change in the amplitude of the motor evoked potential (MEP) induced by a Paired Associative Stimulation (PAS) protocol, expressed as the percentage change between the pre-PAS and post-PAS measurements. The variation represents the degree of brain plasticity induced by the PAS protocol during a session. It will be done during all the assessments of phase A and phase B.

6 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Cortical excitability: Membrane excitability of neurons in the motor cortex
時間枠:6 weeks

It will be assessed by the Resting Motor Threshold (RMT), defined as the minimum stimulation intensity, expressed as a percentage of the Maximum Stimulator Output (MSO), that elicits at least 5 motor evoked potentials (PEM) ≥ 50 µV in 10 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Changes in cortical membrane excitability induced by the PAS protocol
時間枠:6 weeks

It will be assessed by the change (Δ) in RMT induced by the PAS protocol, expressed as the percentage change between the RMT measured immediately after PAS and the RMT measured before PAS. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Overall response of the corticospinal tract
時間枠:6 weeks

It will be assessed by the PEM amplitude at the RMT, defined as the "peak-to-peak" average (µV) calculated from a series of 20 PEMs recorded at the RMT. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Cortical excitability: Conduction and functional integrity of corticospinal tracts
時間枠:6 weeks

It will be assessed by the PEM latency at the RMT, defined as the time (ms) between the magnetic pulse and the onset of the muscle response, averaged over 20 trials. It will be done during each session of phase A and phase B (except on the last day of each phase).

6 weeks
Motor learning performance: general learning effect assessed by SRTT
時間枠:6 weeks

The general learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence).

During the SRTT, the participant must slide their finger from one position to another as quickly as possible, in response to a visual stimulus appearing at one of the four locations on the screen. In the sequenced condition, a sequence of 8 movements is repeated six times per block, while in the random condition, the 48 positions appear in a random order. The blocks follow the same alternation (R-S-S-S-R-S), allowing for the isolation of effects related to the learning of motor sequences.

6 weeks
Motor learning performance: specific learning effect assessed by SRTT
時間枠:6 weeks

The specific learning effect will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

6 weeks
Motor learning performance: retention assessed by SRTT
時間枠:6 weeks

The retention will be assessed by Serial Reaction Time Task SRTT. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

6 weeks
Motor learning performance: general learning effect assessed by Target Jump tasks
時間枠:6 weeks

The general learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the decrease in normalized reaction time (%mRT) between block 2 and block 4 (sequence).

During the Target Jumps tasks, the participant must return their finger to the lower center of the screen before each trial, then slide it toward the target that appears. The target shifts a few centimeters as the participant begins the movement. The blocks alternate according to the pattern R-S-S-S-R-S, with random or systematic shifts, allowing for the exploration of visuomotor adaptation abilities.

6 weeks
Motor learning performance: specific learning effect assessed by Target Jump tasks
時間枠:6 weeks

The specific learning effect will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the increase in %mRT in block 5 (random) compared to block 4 (sequence).

6 weeks
Motor learning performance: retention assessed by Target Jump tasks
時間枠:6 weeks

The retention will be assessed by Target Jump tasks. It will be evaluated during each session of phase A and phase B (except on the last day of each phase). Specifically, this criterion will be evaluated by the change in %mRT between block 6 (sequence) and block 5 (random).

6 weeks
Severity of the symptom that lead to initial treatment prescription
時間枠:6 weeks

It will be reported by the patient using the Patient Global Impression of Severity PGI-S completed at inclusion, on the last day of phase A and last day of phase B.

This scale ranges from 1 ("no discomfort/pain/anxiety") to 4 ("severe"). Each patient will complete only one PGI-S form, corresponding to the symptom being treated by the study drug.

6 weeks
Safety of participants
時間枠:6 weeks

It will be assessed by the spontaneous report on adverse events, assessed at each session.

6 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Emmeline Montané, MD、University Hospital, Toulouse

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年5月1日

研究の完了 (推定)

2028年5月1日

試験登録日

最初に提出

2026年11月5日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月17日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する